PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

doi:10.1084/jem.180.1.283

This Article

	Full Text (PDF, 2516K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Vallat, V. P.
	Articles by Krueger, J. G.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Vallat, V. P.
	Articles by Krueger, J. G.


Social Bookmarking

	What's this?

ARTICLES

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

VP Vallat, P Gilleaudeau, L Battat, J Wolfe, R Nabeya, N Heftler, E Hodak, AB Gottlieb and JG Krueger
Laboratory for Investigative Dermatology, Rockefeller University, New York, 10021.

Psoriasis is characterized by alterations in both the epidermis and dermis of the skin. Epidermal keratinocytes display marked proliferative activation and differentiate along an "alternate" or "regenerative" pathway, while the dermis becomes infiltrated with leukocytes, particularly interleukin 2 (IL-2) receptor-bearing "activated" T cells. Psoralens, administered by the oral route, have therapeutic effects in psoriasis when photochemically activated by ultraviolet A light (PUVA therapy). Recently psoralen bath therapy has been introduced to more effectively deliver this agent to the diseased skin. We have correlated the efficacy of PUVA bath therapy with its effects on specific molecular and cellular parameters of disease, in 10 consecutive patients with recalcitrant psoriasis. Rapid clearing of lesions occurred in 8 out of 10 patients. Biopsies were taken from lesional and nonlesional skin before and after a single round of therapy, and observation was continued in our Clinical Research Center at The Rockefeller University. Enumeration of cycling keratinocytes with the Ki-67 monoclonal antibody showed that PUVA reduced cell proliferation by 73%. The pathological increase in insulin-like growth factor 1 (IGF-1) receptors was reversed, whereas epidermal growth factor (EGF) receptors, which are also increased in psoriasis, remained unchanged. Keratinocyte proteins that are expressed in abnormal sites of the epidermis during psoriasis, i.e., keratin 16, filaggrin, and involucrin, were, after PUVA treatment, localized to their normal sites. Epidermal and dermal T-lymphocytes (CD3+), as well as CD4+, CD8+, and IL-2 receptor+ subsets, were strongly suppressed by PUVA, with virtual elimination of IL-2 receptor+ T cells in some patients. Consistent with diminished lymphocyte activation, HLA-DR expression by epidermal keratinocytes was markedly reduced in treated skin. In comparison to cyclosporine treatment of psoriasis, PUVA therapy leads to more complete reversal of pathological epidermal and lymphocytic activation, changes which we propose to be the cellular basis for a more sustained remission of disease after PUVA treatment.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Stern, R. S. (2007). Psoralen and Ultraviolet A Light Therapy for Psoriasis. NEJM 357: 682-690 [Full Text]
Rittie, L., Kansra, S., Stoll, S. W., Li, Y., Gudjonsson, J. E., Shao, Y., Michael, L. E., Fisher, G. J., Johnson, T. M., Elder, J. T. (2007). Differential ErbB1 Signaling in Squamous Cell versus Basal Cell Carcinoma of the Skin. Am. J. Pathol. 170: 2089-2099 [Abstract] [Full Text]
Wahba, I. M., White, K., Meyer, M., Simpson, E. L. (2007). The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy--report of two cases and review of the literature. Nephrol Dial Transplant 22: 631-636 [Full Text]
Wolf, P., Nghiem, D. X., Walterscheid, J. P., Byrne, S., Matsumura, Y., Matsumura, Y., Bucana, C., Ananthaswamy, H. N., Ullrich, S. E. (2006). Platelet-Activating Factor Is Crucial in Psoralen and Ultraviolet A-Induced Immune Suppression, Inflammation, and Apoptosis. Am. J. Pathol. 169: 795-805 [Abstract] [Full Text]
Lowes, M. A., Chamian, F., Abello, M. V., Fuentes-Duculan, J., Lin, S.-L., Nussbaum, R., Novitskaya, I., Carbonaro, H., Cardinale, I., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Wittkowski, K. M., Papp, K., Garovoy, M., Dummer, W., Steinman, R. M., Krueger, J. G. (2005). Increase in TNF-{alpha} and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA 102: 19057-19062 [Abstract] [Full Text]
Ellis, C. N., Krueger, G. G., the Alefacept Clinical Study Group, (2001). Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes. NEJM 345: 248-255 [Abstract] [Full Text]
Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., Krueger, J. G. (2000). Blockade of T Lymphocyte Costimulation with Cytotoxic T Lymphocyte-associated Antigen 4-Immunoglobulin (CTLA4Ig) Reverses the Cellular Pathology of Psoriatic Plaques, Including the Activation of Keratinocytes, Dendritic Cells, and Endothelial Cells. JEM 192: 681-694 [Abstract] [Full Text]
Robert, C., Kupper, T. S. (1999). Inflammatory Skin Diseases, T Cells, and Immune Surveillance. NEJM 341: 1817-1828 [Full Text]
Nickoloff, B. J. (1999). The Immunologic and Genetic Basis of Psoriasis. Arch Dermatol 135: 1104-1110 [Full Text]
Coven, T. R., Murphy, F. P., Gilleaudeau, P., Cardinale, I., Krueger, J. G. (1998). Trimethylpsoralen Bath PUVA Is a Remittive Treatment for Psoriasis Vulgaris: Evidence That Epidermal Immunocytes Are Direct Therapeutic Targets. Arch Dermatol 134: 1263-1268 [Abstract] [Full Text]